COMP <GO>
DBD vs JXG // EV/EBITDA & P/E VALUATION
Diebold Nixdorf Incorporated (NYSE) VS. JX Luxventure Group Inc. (NASDAQ) • 15-METRIC TALLY: DBD 1
— JXG 1
■ METRIC PARITY
LAST: $59.14 (+1.84%) • MKT CAP: $1.99B
valuation
10.6x
LAST: $7.04 (+1.44%) • MKT CAP: $84.9M
valuation
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (DBD VS. JXG)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | DBD | JXG | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 25.30% | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 11.50% | — | — | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | 10.6x | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | 15.14% | — | — | TIE | /fcf-yield <GO> |
| Operating Margin | 6.40% | — | — | TIE | /operating-margins <GO> |
| Net Profit Margin | 2.50% | — | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | 1.50% | — | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 1.79 | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | — | — | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 27.7 | 46.5 | -18.83 | JXG | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 19.5x | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $1.99B | $84.9M | $1.90B | DBD | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | DBD REV | JXG REV | DBD GROSS % | JXG GROSS % | DBD FCF | JXG FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $3.81B | — | 25.3% | — | $300.7M | — |
| FY 2024 | $3.75B | — | 24.5% | — | $149.2M | — |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
DBD // BETA —
JXG // BETA —